

Index

- ablation, local, 6, 195, 197–8
see also cryoablation; high-intensity focused ultrasound (HIFU) treatment; percutaneous ethanol injection (PEI); radiofrequency ablation (RFA)
- abscess, 68–9, 84–5
 following cryoablation, 193–4
- aflatoxin, 2
- alpha-fetoprotein (AFP), 119
 hepatocellular carcinoma, 3,
 screening, 4
- angiogenesis, 9, 11
 inhibition, 9, 10, 174
 in colorectal cancer, 16
see also blood supply
- arterial tumor vessels, 35–7
- Barcelona Clinic Liver Cancer Staging Classification, 101, 130–1
- Bernadino needle, 111–12
- bevacizumab, 11, 17
 colorectal cancer therapy, 16
- biliary complications, cryoablation, 195
- billing team, 207
- bio-heat equation, 151, 169–70
- biopsy
 hepatocellular carcinoma, 3
 liver metastasis, 40
- bipolar electrode arrays, 171
- blood flow modulation during radiofrequency ablation, 152–3, 173–4
 heat sink minimization, 174
 tissue perfusion, 174
- blood supply, 74
 advanced hepatocellular carcinoma, 35–7
 arterial tumor vessels, 35–7
 portal vein, 37
 sinusoid-like blood spaces, 37
 venous tumor vessels, 37
 pre-liver ablation imaging, 45
 small hepatocellular carcinoma, 28–30
see also angiogenesis
- breast cancer metastases, 139–40
- capecitabine, 14
- capillarization, 37
- carcinoembryonic antigen (CEA) level, 134–5
- cetuximab, 16, 17
- chemoembolization *see* transarterial chemoembolization (TACE)
- chemotherapy, 8–9
 angiogenesis inhibition, 9, 10, 16
 colorectal cancer, 14–16, 184
 downstaging of liver metastases, 16–17
 combination therapy, 11–12, 14–16
 resistance, 11–12
 sorafenib, 10–12
 with thermal ablation, 175
see also transarterial chemoembolization (TACE)
- Chiba needle, 111–12, 114
- cholangiocarcinoma, differential diagnosis, 40
- cirrhosis, 2, 108
 liver metastasis frequency and, 38
 prognosis and, 4
 resection and, 108–9
- cisplatin, use in chemoembolization, 77
- clinic set-up, 205–6
see also radiofrequency ablation (RFA) service
- coagulation necrosis induction
 bio-heat equation, 151, 169–70
 energy sources, 168
 in radiofrequency ablation, 151–2, 168–9
- colorectal cancer (CRC), 17–18, 181–2
 hepatic metastases, 13–17, 133, 181–2,
 183–4
 chemoembolization, 82
 clinical risk score, 135
 radiofrequency ablation, 13–14, 160–2,
 surgical treatment, 13, 128, 133–5
see also liver metastases
- systemic therapy, 14–16
 angiogenesis inhibition, 16
- communication, 208–9
- complications,
 cryoablation, 192–5
 percutaneous ethanol injection, 117

214 Index

- complications (cont.)
 radiofrequency ablation, 68–9
 transarterial chemoembolization, 83–5
- computed tomography (CT), 47–50
 cryoablation monitoring, 189, 190–1, 195, 197–8
 hepatocellular carcinoma, 2–3
 multidetector-row CT (MDCT), 47–50, 51–2,
 60–1, 64
 indications for, 50
 protocols, 50
 percutaneous ethanol injection follow-up, 119
 PET/CT, 53, 66–8
 post-liver ablation follow-up, 55, 57–8,
 60–1, 66–8
 residual or recurrent tumor, 64
 radiofrequency ablation guidance, 153–7
- contrast-enhanced imaging, 45–7
 ultrasonography (CEUS), 47, 48
- cracking, liver, 193
- cryoablation, 185–8
 ablation zone monitoring, 188–91
 complications, 192–5
 abscess, 193–4
 biliary complications, 195
 hemorrhage, 192–3
 post-ablation syndrome, 194–5
 tumor lysis syndrome (cryoshock), 194
 tumor seeding, 194
 follow-up, 195–7
 multiple freeze cycles, 189–90
 patient selection, 181
 pneumothorax risk, 187
 post-procedure management, 192
 probe placement, 185–8
 intraoperative, 187–8
 ultrasound guidance, 187–8,
 sedation, 191
 cryoshock, 194
 cytokeratin 7 (CK 7), 40
 cytokeratin 20 (CK 20), 40
- decompensation, hepatic, 84
 diffuse fatty change, 30
 donor organs, 5
 doxorubicin, 8
 use in chemoembolization, 77
- dysplastic nodules (DN), 26–7
 high-grade, 26–7
 low-grade, 26
- embolization *see* transarterial chemoembolization (TACE)
- endocrine therapies, hepatocellular carcinoma, 9
 epidermal growth factor (EGF), 11
 inhibition in colorectal cancer, 16
- epirubicin, use in chemoembolization, 77
- erlotinib, 11,
 Exablate, 98–9
 extrahepatic tumor extension screening, 53–4
- 18-F-fluorodeoxyglucose-PET (FDG-PET)
 extrahepatic tumor extension screening, 53
 post-liver ablation follow-up, 67–8
- fibrolamellar carcinoma (FLC), 34
- 5-fluorouracil (5-FU), 14–15,
 follow-up, 210–11
 cryoablation, 195–7
 percutaneous ethanol injection, 117–19
 post-liver ablation imaging, 55–68
 expected imaging (complete ablation), 57–61
 imaging protocol, 55–7
 indeterminate imaging, 61–4
 residual and recurrent imaging, 64–5
- gastroduodenal ulceration, 85
 gastrointestinal (GI) carcinoids, 136
 gastrointestinal stromal tumor (GIST), 139
 gelatin sponge, 76–7
 germ cell tumor metastases, 140
- hemorrhage, 192–3
 hepatectomy *see* resection
 hepatic artery occlusion, 85
see also transarterial chemoembolization (TACE)
- hepatic metastases *see* liver metastases
 hepatitis B virus (HBV), 1–2, 100, 108
 hepatitis C virus (HCV), 2, 108
 hepatocellular carcinoma (HCC), 1–12, 18, 25, 99–100,
 108, 181, 182–3
 ablation, 6
 high-intensity focused ultrasound (HIFU), 101–4,
 image-guided, 157–60
 percutaneous ethanol injection (PEI), 6, 109–23
 radiofrequency ablation, 6, 158–60,
see also specific ablation techniques
 advanced HCC, 31–4, 35–7
 angioarchitecture, 35–7
 gross appearance, 31–2
 histology, 32–4
 moderately differentiated, 33–4
 poorly differentiated, 34
 well differentiated, 32–3
- angiogenesis inhibition, 9, 10
 transarterial chemoembolization (TACE), 6–8,
 78–81, 102
- chemotherapy, 8–9, 10–12
 classification, 100, 101, 129–31
 diagnosis, 2–3
 diffuse infiltrative, 100
 early detection, 25
 endocrine therapies, 9
 epidemiology, 1–2
 etiology, 1–2
 liver resection, 4, 44, 108–9
 massive type, 100
 nodular, 100
 pathology, 25–37
 premalignant lesions, 26–7
 prognosis, 4

- radiation therapy, 12
- recurrence, 8, 64–5, 183
- residual tumor, 64–5
- risk factors, 2
- screening, 3–4, 182–3
- staging, 100, 101, 129–31, 148
- surgical treatment, 4, 44, 108–9, 127, 128, 129–32, 157–8, 183
 - safety improvements, 127–9
 - transplantation, 5, 109, 131, 132, 157–8
- variants, 34
 - fibrolamellar HCC, 34
 - sarcomatoid HCC, 34
 - scirrhous HCC, 34
- well-differentiated early stage HCC, 27–31
 - distinctly nodular type, 30
 - evolution to advanced stage, 30
 - nodule-in-nodule appearance, 30–1
 - vaguely nodular type, 27–30
- high-intensity focused ultrasound (HIFU) treatment, 92, 104
 - adverse events, 103
 - applications, 97
 - limitations, 103–4
 - liver tumors, 101–4
 - metastases, 102–4
 - with transarterial chemoembolization, 102
 - mechanisms of tissue change, 93–4
 - principles, 92–7
 - treatment devices and procedures, 97–9
- hospital admitting privileges, 205
- ice crystal formation, 182
 - see also* cryoablation
- image-guided radiofrequency ablation, 148–62
 - ablation technique, 150–3
 - eligibility criteria, 148–50
 - imaging, 153–7
 - outcomes, 157–62
 - colorectal hepatic metastases, 160–2,
 - hepatocellular carcinoma, 157–60,
 - pretreatment assessment, 148–50
 - see also* radiofrequency ablation (RFA)
- internal marketing, 208
- internally cooled electrodes, 171
- Interventional Oncology (IO), 203–4
- irinotecan, 14, 15
- leiomyosarcoma, metastatic, 139
- lesion enhancement pattern, 64
- liver cracking, 193
- liver metastases, 13–17, 101, 133, 181–2, 183–4
 - biopsy, 40
 - chemoembolization
 - colorectal metastases, 82
 - neuroendocrine metastases, 82–3
 - clinical risk score, 135
 - downstaging of, 16–17
 - gross appearance, 38–40
 - high-intensity focused ultrasound (HIFU)
 - treatment, 102–4
 - incidence, 37–8
 - cirrhosis relationship, 38
 - radiofrequency ablation, 13–14, 161
 - image-guided, 160–2
 - recurrence, 64–5, 136, 184
 - residual tumor, 64–5
 - surgical resection, 13, 44, 127, 132–40, 141, 184
 - colorectal cancer metastases, 128, 133–5
 - neuroendocrine tumor metastases, 136–8,
 - other tumor metastases, 139–40
 - safety improvements, 127–9
- liver structure, 94
- liver transplantation, 5, 109, 132, 157–8
 - eligibility criteria, 5, 131, 132
 - neuroendocrine metastases and, 138
- magnetic resonance imaging (MRI), 50–2
 - contrast media, 51
 - cryoablation monitoring, 189
 - hepatocellular carcinoma, 2–3
 - percutaneous ethanol injection follow-up, 119
 - post-liver ablation follow-up, 58, 65
 - protocols, 53
 - radiofrequency ablation guidance, 153–7
- marketing, 207–8
 - external, 207–8
 - internal, 208
- melanoma, metastatic, 140
- metastases *see* liver metastases
- mitomycin-C, use in chemoembolization, 77
- Model-JC Tumor Therapy System, 99
- multidetector-row computed tomography (MDCT), 47–50, 51–2
 - indications for, 50
 - post-liver ablation follow-up, 60–1, 64
 - protocols, 50
- multipolar electrode arrays, 171
- multitine electrode arrays, 170–1
- neovascularization, 37
- neuroendocrine tumors, 136
 - metastases, 82–3
 - surgical treatment, 136–8,
 - nolatrexed, 8–9
- oily chemoembolization, 77–8
- oxaliplatin, 14–15, 17
- pale body, 34
- palliative therapies, 74
 - neuroendocrine metastases, 137–8
 - see-also* specific therapies
- pancreatitis, 85
- patient management, 209–10
- PEIT needle, 111–12, 114

216 Index

- percutaneous ethanol injection (PEI), 6, 109–23
 complications, 117
 equipment, 110–12
 evaluation of effectiveness, 117–19
 indications and contraindications, 116–17
 multimodality therapy, 122
 pretreatment assessments, 110
 procedure, 112–15
 results, 120–2
 recurrence, 121–2
 versus radiofrequency ablation, 122, 158
 volume of alcohol required, 115
- perfusion electrodes, 171–2
- pneumothorax, 187
- polyvinyl alcohol (PVA), 77
 polymeric beads, 87
- portal vein, 37
 occlusion, 86
see also blood supply
- positron emission tomography (PET)
 18-F-fluorodeoxyglucose-PET (FDG-PET), 53, 67–8
 extrahepatic tumor extension screening, 53–4
 PET/CT, 53–4, 66–8
 post-liver ablation follow-up, 66–8
- post-ablation syndrome, 194–5
- post-procedural follow-up *see* follow-up
- postembolization syndrome (PES), 84
- professional team, 206–7
- prostate cancer, 97
- pseudoglands, 33–4
- Quadrafuse needle, 112, 114–15
- radiation therapy, 12
 with radiofrequency ablation, 175–6
- radiofrequency ablation (RFA), 44–5, 69–70, 150–3, 167
 bio-heat equation, 151, 169–70
 coagulation necrosis induction, 151–2, 168–9
 complications, 68–9, 162
 contraindications, 44–5
 creating meaningful volumes of ablation, 170
 electrode design modification, 170–2
 algorithms for effective heating, 172
 bipolar/multipolar arrays, 171
 internally cooled electrodes, 171
 multitine arrays, 170–1
 perfused electrodes, 171–2
 eligibility criteria, 148–50
 follow-up, 210–11
 goals of, 167–8
 hepatocellular carcinoma, 6, 158–60, image-guided, 148–62
 imaging techniques, 153–7
 liver metastases, 13–14, 160–2, modulating tissue blood flow, 173–4
 heat sink minimization, 174
 tissue perfusion, 174
 modulating tissue characteristics, 172–3
 electrical conductivity, 173
 thermal conductivity, 173
 multimodality therapy, 122
 patient management, 209–10
 post-liver ablation imaging, 55–68, 69
 expected imaging (complete ablation), 57–61
 imaging protocol, 55–7
 indeterminate imaging (need follow-up), 61–4
 liver tissue changes, 55
 management strategies, 57
 PET and PET/CT imaging, 66–8
 residual and recurrent imaging, 64–5
- pre-liver RFA imaging, 45–54, 69
 dynamic imaging role, 45–7
 lesion evaluation, 47–52
 liver blood supply, 45
 screening for extrahepatic extension, 53–4
- service set-up *see* radiofrequency ablation (RFA) service
- synergistic therapies, 174–6
 chemotherapy, 175
 radiation therapy, 175–6
 technique, 150–3
 versus percutaneous ethanol injection, 122, 158
- radiofrequency ablation (RFA) service, 211
 billing team, 207
 clinic set-up, 205–6
 communication, 208–9
 hospital admitting privileges, 205
 marketing, 207–8
 patient management, 209–10
 professional team, 206–7
 training, 204–5
- Raf/MEK/ERK signaling pathway, 10
- referral building, 207–8
- renal cell carcinoma metastases, 139
- renal failure, 85
- reproductive tract tumor metastases, 140
- resection, 44, 127
 hepatocellular carcinoma, 4, 44, 108–9, 127, 128, 129–32, 157, 183
 liver metastases, 13, 44, 127, 132–40, 141, 184
 from colorectal cancer, 128, 133–5
 from neuroendocrine tumors, 136–8,
 from other tumors, 139–40
 safety improvements, 127–9,
- sarcoma, metastatic, 139
- sarcomatoid hepatocellular carcinoma, 34
- scirrhous hepatocellular carcinoma, 34
- screening
 extrahepatic tumor extension, 53–4
 hepatocellular carcinoma, 3–4, 182–3
- sedation, 191
- sinusoid-like blood spaces, 37
- sorafenib, 10–12
- stromal invasion, 28

- sunitinib, 11
- surgical resection *see* resection
- thermal ablation *see* radiofrequency ablation (RFA)
- tissue blood flow modulation *see* blood flow modulation during radiofrequency ablation
- tissue electrical conductivity modulation, 173
- tissue thermal conductivity modulation, 173
- training, radiofrequency ablation, 204–5
- transarterial chemoembolization (TACE), 6–8, 74–5, 87
 - colorectal metastases, 82
 - contraindications, 7–8, 86–7
 - efficacy, 78
 - embolic materials, 76–8
 - choice of chemotherapeutic agents, 77
 - choice of embolic particles, 76–7
 - choice of emulsion, 77–8
 - embolization procedure, 75–6
 - hepatocellular carcinoma therapy, 6–8, 78–80
 - role as neoadjuvant therapy, 80–1
 - with high intensity focused ultrasound, 102
 - multimodality therapy, 122
 - neuroendocrine tumor metastases, 82–3
 - new developments, 87
 - patient selection, 86–7
 - optimum efficacy, 86
 - optimum tolerability, 86–7
 - post-procedural care, 76
 - pre-treatment assessment, 75
 - toxicity, 83–5
 - postembolization syndrome, 84
 - with radiofrequency ablation, 175
- transforming growth factor alpha (TGF), 11
- transplantation *see* liver transplantation
- trisacryl gelatin spheres, 77
- tumor lysis syndrome (cryoshock), 194
- ultrasonography (US), 47
 - contrast-enhanced (CEUS), 47, 48
 - cryoablation monitoring, 189
 - cryoablation probe placement guidance, 187
 - intraoperative (IOUS), 187–8
 - percutaneous ethanol injection follow-up, 119
 - radiofrequency ablation guidance, 153–7
 - see also* high-intensity focused ultrasound (HIFU) treatment
- unpaired arteries, 35–7
- vascular endothelial growth factor (VEGF), 9
 - inhibition, 9, 10
 - in colorectal cancer, 2
- venous tumor vessels, 37